| (Mean ± SD) CD62L | p value |
Donor relation |
|
|
Related donor (n = 37) | 41.85 ± 16.73 | 0.051 |
Nonrelated donors (n = 12) | 53.64 ± 17.28 |
|
Antibody induction therapy |
|
|
ATG (n = 34) | 42.25 ± 18.14 |
|
Basiliximab (n = 12) | 42.28 ± 13.60 | 0.172 |
No antibody induction (n = 4) | 62.40 ± 15.40 |
|
Immunosuppression protocol |
|
|
CsA based protocol (n = 14) | 48.15 ± 15.56 | 0.195 |
Tacrolimus based protocol (n = 32) | 43.76 ± 18.56 |
|
m-TORI low CsA protocol (n = 4) | 30.50 ± 11.03 |
|
CNI used |
|
|
CsA (n = 17) | 48.15 ± 15.56 | 0.144 |
Tacrolimus (n = 32) | 42.93 ± 18.35 |
|
CMV status |
|
|
CMV RT-PCR –ve (n = 40) | 45.85 ± 18.08 | 0.326 |
CMV RT-PCR +ve (n = 10) | 39.81 ± 14.12 |
|
Previous PRAR episodes |
|
|
No PRAR (n = 16) | 45.46 ± 15.26 | 0.960 |
1episode PRAR (n = 9) | 43.82 ± 20.36 |
|
≥2 episodes PRAR (n = 25) | 44.60 ± 18.41 |
|
Previous BPAR episodes |
|
|
No BPAR (n = 16) | 40.79 ± 21.71 | 0.430 |
Yes BPAR (n = 33) | 46.65 ± 14.98 |
|
Pathological evidence of CAD |
|
|
No CAD (n = 43 | 44.76 ± 16.26 | 0.91 |
Yes CAD (n = 7) | 44.63 ± 25.07 |
|